Dupilumab Combined With House Dust Mite Allergen Immunotherapy for Atopic Dermatitis: A Systematic Review and Meta-Analysis
In brief
Dupilumab plus dust-mite immunotherapy does not improve atopic dermatitis severity up to a year
A meta-analysis of four studies (138 patients) found that adding house-dust-mite allergen immunotherapy to dupilumab offered no significant reduction in disease severity at 6 or 12 months, and quality of life and safety were unchanged. A modest signal of benefit emerged only after 18 months, but the evidence is very low quality, so larger trials are needed.
- Journal
- Clinical and translational allergy (Q1)
- Published
- 1 August 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Jiale Lian, Ling Ren, Jing Liang, Shuping Guo
- PMID
- 42570326
- DOI
- 10.1002/clt2.70194
Why clinicians should know about it
- Picked for Immunology and Allergy (top studies of the week, 9 August 2026).
- Picked for Dermatology (paper of the day, 9 August 2026): Dupilumab + HDM-AIT, atopic dermatitis
Abstract
BACKGROUND: Dupilumab is effective for moderate-to-severe atopic dermatitis (AD), but sustained disease control after treatment discontinuation remains challenging. House dust mite allergen immunotherapy (HDM-AIT) may provide disease-modifying effects in sensitized patients, but the added value of combining HDM-AIT with dupilumab remains unclear. OBJECTIVE: To evaluate the efficacy and safety of dupilumab combined with HDM-AIT versus dupilumab monotherapy in patients with AD. METHODS: PubMed, Embase, Web of Science, and Cochrane Library were searched from inception to April 21, 2026. Randomized controlled trials and comparative observational studies evaluating dupilumab plus HDM-AIT versus dupilumab alone were included. Disease severity assessed by EASI or SCORAD was pooled using standardized mean differences (SMDs), Dermatology Life Quality Index (DLQI) using mean differences, and adverse events using risk ratios. Random-effects models were applied. The certainty of evidence was assessed using the GRADE approach. RESULTS: Four studies involving 138 patients were included, comprising one randomized controlled trial and three comparative observational studies. Combination therapy showed no significant improvement in disease severity at 6 months (SMD = -0.02, 95% CI -0.41 to 0.36; I2 = 0%) or 12 months (SMD = 0.53, 95% CI -1.10 to 2.16; I2 = 93%). At 18 months, the pooled estimate suggested a possible benefit of combination therapy for disease severity, although the certainty of evidence was very low (SMD = -0.96, 95% CI -1.76 to -0.17; I2 = 61%), although evidence was limited. At the follow-up closest to 30 months, the effect favored combination therapy but was not significant (SMD = -1.16, 95% CI -2.56 to 0.24; I2 = 87%). No significant differences were observed in DLQI, overall adverse events, or ocular adverse events. CONCLUSION: Current evidence regarding dupilumab combined with HDM-AIT for AD remains limited and inconclusive. Although an exploratory signal of improved disease severity was observed at 18 months, the available data did not demonstrate a statistically significant difference in adverse events, and the certainty of evidence was very low for all evaluated outcomes. Further adequately powered randomized controlled trials with standardized protocols, outcome definitions, and long-term follow-up are needed.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.